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Malaria infestation in pregnancy is a global 
health concern
, where it is a major public health 
1,2concern and cause of death . Although the 
continent is home to about 15.2 percent of the 
world's population, 500 million people are 
infested by malaria annually, while 1 million of 
these die from malaria,
75,000 to 
 200,000 infant deaths are associated with 
 because half of the world's 
population is at risk of malaria, with majority of 
them in Africa
 about 24 million 
pregnancies are threatened, and 
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ABSTRACT
Background: Sulphadoxine-pyrimethamine (SP) intermittent preventive treatment in pregnancy (IPTp), is 
the malaria prophylaxis that is recommended in malaria endemic areas. Increasing reports of resistance to SP 
across the globe, make appraisal of its efficacy to be necessary in health facilities that use it.
Objective: To determine the efficacy of SP – IPTp in the prevention of malaria in pregnancy using Proguanil 
chemoprophylaxis as the gold standard, in Aminu Kano Teaching Hospital, Kano, Nigeria.
 Methods: In this prospective study, 300 primigravid women were enrolled and assigned by block 
randomization to SP – IPTp (cases) or proguanil chemoprophylaxis (control) group. Each group consisted of 
150 women. Study variables of interest were packed cell volume (PCV) at recruitment and at 34 weeks 
gestation, peripheral malaria parasitaemia, severe anaemia at 34 weeks gestation, and the frequency of 
clinical malaria during the study period in the two groups. The data obtained were recorded using tables. 
Students't-test, Z-test and chi-square test were used to compare means and proportions respectively for 
statistically significant differences, setting the level of significance at P < 0.05. 
Results: There was statistically significant increase in the PCV between recruitment and at 34 weeks in each 
group (P < 0.05), but there was no statistically significant difference in the PCV, peripheral malaria 
parasitaemia and frequency of clinical malaria between the two groups at 34 weeks gestation (P > 0.05).
Conclusion: SP-IPTp has similar effectiveness as proguanil chemoprophlaxis. SP-IPTp is still effective in 
the prevention of malaria in pregnancy at Aminu Kano Teaching Hospital.   
Keywords ; Sulphadoxine-pyrimethamine, proguanil, malaria, pregnancy.
INTRODUCTION
2-4
malaria infestation in pregnancy .
Falciparum malaria is an important cause of 
maternal, perinatal and neonatal morbidity in 
high transmission settings in sub-Saharan 
2
Africa . 
 malaria in pregnancy 
 
Besides the number of people at risk in 
sub-Saharan Africa,
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commonly co-exist with conditions that alter the 
acquired maternal partial immunity against 
malaria infestation, like haemoglobimopathies, 
H u m a n  I m m u n o d e f i c i e n c y  V i r u s  
infection/Acquired Immunodeficiency 
Syndrome (HIV/AIDS), poverty and poor 
nutrition with micronutrient imbalances, pre-
existing anaemia, Tuberculosis, diarrhoeal 
d iseases ,  sep t icaemia ,  and  Tropica l  
Splenomegaly Syndrome (TSS), which 
exacerbate the impact of pregnancy-associated 
 5-9malaria. . In addition, early pregnancy losses 
and perinatal mortality from increased risk of 
vertical transmission, low birth weight babies 
from prematurity and intrauterine growth 
restriction, and intrauterine fetal death have 
9-12been documented .
The integration into the antenatal programs of 
effective antimalarial interventions like IPT  p,
use of long lasting insecticide treated bed nets 
(ITNs), advise to rid their environments of 
breeding places for mosquitoes, indoor spraying 
of insecticides and where possible fumigation of 
their surroundings, together with the use of 
artemisinin-based combination therapy for the 
13treatment of cases with clinical malaria , 
presents a new opportunity for large scale 
malaria control, and progress towards targets set 
by Roll Back Malaria Partnership within the 
framework of the Millennium Development 
12Goals .
In many countries in sub-Saharan Africa, SP-
IPTp has proven efficacious in reducing the 
13,14burden of pregnancy associated malaria , and 
two doses of SP were found to be enough to 
significantly reduce the prevalence of peripheral 
15and placental malaria parasitaemia , but its 
effectiveness is being threatened by increasing 
levels of parasite resistance to SP across Africa 
 15-19and in South East Asia . This may seriously 
undermine the benefits of national SP-IPTp 
16programs in this region . Hence there is an 
urgent need for on-going appraisal of the 
efficacy SP for IPTp, in health facilities that use 
the drug for prevention of malaria in pregnancy, 
in order to detect early development of 
resistance to the drug, in event of which 
alternative drug regimens for IPTp can be 
introduced, and failure of preventive therapy 
16can be avoided . 
It is against this background that an appraisal of 
the efficacy of the antimalarial intervention 
using SP - IPTp in Aminu Kano Teaching 
Hospital, Kano, Nigeria, was carried out using 
proguanil chemoprophylaxis as the gold 
standard, so that recommendations can be made 
on whether to continue the use of SP for IPTp or 
to develop alternative drug regimens. 
METHODOLOGY
This is a prospect study to determine the efficacy 
of SP-IPTp in the prevention of malaria in 
pregnancy among primigravida who attended 
the antenatal clinic in Aminu Kano Teaching 
Hospital, Kano, Nigeria, and consented to be 
included in this study between January and June 
2011, using proguanil chemoprophylaxis as the 
gold standard, which was based on the findings 
17of Flemin et al  in Zaria, Nigeria, which attested 
to the efficacy of proguanil, with the findings 
that resistance to proguanil is infinitely minimal. 
Only primigravidae were recruited for 
uniformity, and because they have lower 
immunity to malaria than women of higher 
14parity , and will be more representative of the 
effect of malaria prevention in pregnancy. 
The women were recruited at the booking clinic. 
The inclusion criteria were primigravidae with 
certain dates (last menstrual period confirmed 
with ultrasound scan), who were carrying 
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singleton gestation between 16 and 24 weeks of 
pregnancy, who gave informed consent to 
participate in the study, while the exclusion 
criteria were women with severe anaemia (PCV 
< 24%), sickle  cell anaemia, multiple 
pregnancies, urinary tract infection (acute 
pyelonephritis), HIV/AIDS, and previous 
adverse reaction to Sulphonamides – 
pyrimethamine, proguanil or Artemisinin- 
Lumefantrine combination. Participants who 
developed clinical malaria during the study 
period in the two groups were excluded from 
follow-up.
In this prospective study, 300 primigravid 
women were enrolled and assigned by block 
randomization to the SP – IPTp (cases) or 
Proguanil chemoprophylaxis (control) groups. 
Each group consisted of 150 women. 
All participating clients who fulfilled the 
inclusion criteria were given Artemisinine 
combination therapy (ACT) at recruitment in 
the booking clinic to clear initial parasitaemia, 
before SP and proguanil hydrochloride tablets 
were given to their respective groups at the next 
clinic visit a week later. ACT that was used was 
Artemether-lumefantrine, 4 tablets twice daily 
for 3 days, each tablet contained artemether 
80mg and lumefantrine 480mg, with the first 
dose given as directly observed therapy (DOT) 
at recruitment in the booking clinic.
Participants in the SP-IPTp group  received two 
adult doses of S-P at 4 weeks interval between 
16 and 24 weeks of gestation (3 tablets at once, 
each tablet containing 500mg Sulphadoxine, 
and 25mg pyrimethamine) as directly observed  
therapy during the clinic visits, while 
participants in the proguanil chemoprophylaxis 
group received 100mg oral proguanil daily, with 
doses that coincided with clinic visits taken 
under directly observed therapy, and other doses 
were double checked for compliance by looking 
at the remaining proguanil tablets in the 
container, to ascertain the quantity that  have 
been used before clinic visits. Subjects in both 
groups continued with routine antenatal 
visits/care, and were all on routine haematinics. 
The participants were counseled on the need to 
strictly comply with medication
Study variables of interest were socio-
demographic characteristics of the women, the 
use of ITNs, maternal packed cell volume (PCV) 
at recruitment and at 34 weeks gestation, 
peripheral malaria parasitaemia and the 
frequency of severe anaemia at 34 weeks 
gestation, and the frequency of clinical malaria 
during the study period in the two groups. 
The data obtained were recorded using tables. 
Statistical analysis was done using computer 
software SPSS Version 11.0, Illinois, USA. 
Qualitative data were presented using 
percentages and frequencies, while quantitative 
data were presented using mean and standard 
deviation. Chi-square test and Fisher exact test 
were used to compare qualitative variables, 
while Students'-test and Z-test were used to 
compare quantitative variables for statistical 
significance. A P-value of less than 0.05 was 
considered significant. 
Sample Size Determination
18 Nahlen et al, in a study done in Ilorin Nigeria, 
found a 29.7%(11/37) parasitologic failure rate 
with antimalarial intervention in pregnancy. 
Using the result obtained in this study, and 
accepting a study power of 80%, confidence 
interval of 90%, study to control ratio of 1:1, and 
an acceptable dropout rate of 10%, the sample 
size for each group was then determined using 
the statistical formula for comparison of 
proportions as follows:-
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RESULTS
A total of 300 clients, who fulfilled the inclusion 
criteria were recruited into this study, and using 
block randomization, they were divided into two 
groups of 150 participants each. Twelve 
participants were lost to follow up (7 from the SP 
group, and 5 from the proguanil group). Nine 
participants (5 (3.5%) from SP group, and 4 
(2.8%) from proguanil group) developed 
clinical malaria during the study and were 
excluded from follow-up, which left a total of 
279 participants at the end of the study, with 138 
participants in the SP group and 141 participants 
in the proguanil group. Occurrence of clinical 
malaria among the participants during the study 
period did not show statistically significant 
difference between the two groups (Fisher exact 
= 0.47). They were all treated with oral 
arthemeter-lumefantrine on outpatient basis, 
with complete clinical remission. There was no 
case of severe anaemia in the two groups at 34 
weeks gestation. The use of insecticide treated 
bednets in the SP was 2.7% and 3.0% for 
proguanil group, with no statistically significant 
2difference between the two groups (X  = 0.07, P 
= 0.788). 
Table 1 shows the socio-demographic 
characteristics of the participants in the two 
groups.  The mean age (Z = 1.62, P = 0.115), 
mean gestational age at recruitment (Z= 0.67, P 
2= 0.502), occupation (X  = 1.44, P = 0.837), 
2educational status (X  = 1.18, P = 0.757) and 
2tribe (X  = 0.55, P = 0.908) of the participants did 
not show statistically significant difference 
between the two groups. 
Table 2 shows the mean packed cell volume 
between the two groups at recruitment and at 
34 weeks gestation. The mean PCV in the SP 
and proguanil groups at recruitment were 32.1 ± 
3.1% and 32.2 ± 2.85% respectively, which did 
Zá = 1.96; for the significance level of 0.05, that 
is used in this study. 
Zâ = 0.84; for the power of the test of 80% that 
was used in this study to compare between the 2 
groups.  
f = the proportion of study participants who are 
expected to be lost to follow up in this study 
(attrition) = 10% (0.1).
Therefore, the minimum sample size required 
for each study group for it to be statistically 
significant was:
n =       1   x   (2 x    (Za+ Zb)2 x P x(1- P)  
                    (1 - f)                (PO – P1)
2  
  
Where n = minimum sample size
Po = the proportion of participants that are 
expected to have parasitaemia at 34 weeks 
gestation = 0.297.
P  = the efficacy of SP-IPTp among the 1
participants would be determined if the 
parasitaemia rate among them at 34 weeks 
gestation is reduced by 50%.
                            =   50   x 0.297  
                                 100                         
                            =     0.149  
P = is the pooled value.  P = Po + P1   = 0.223  
                               2  









= 1.1 x    2 x 7.84 x 0.223 x 0.777  
         0.219  
= 1.1 x 123.7 
= 136 subjects per group approximately + 10% attrition
=           150 subjects per group approximately.
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not show any statistically significant difference 
between the two groups (Z = 0.39, P= 0.731). 
The mean PCV at 34 weeks gestation was 35.0 ± 
2.5% and 35.4 ± 3.2% for SP and proguanil 
groups respectively, which also did not show 
statistically significant difference between the 
two groups (Z = 1.85, P= 0.074), but there was 
statistically significant increase between 
recruitment and at 34weeks gestation in the SP 
group (Z = 2.40, P = 0.021), and the proguanil 
group (Z = 9.14, P < 0.001).
Table 3 shows the number of participants with 
malaria parasitaemia at 34 weeks gestation in 
the two groups. Among the SP group, 9 
participants (6.3%) had malaria parasitaemia, 
while 5 (5.7%) had in the proguanil group at 34 
weeks gestation. There was no statistically 
significant difference in the number of 
participants with malaria parasitaemia in the 
2two groups at 34 weeks gestation (X  = 0.75, P = 
0.388).     
DISCUSSION
In this study, there was no significant difference 
in the socio-demographic characteristics of the 
participants as well as the use of ITNs in the two 
groups. This would have eliminated any bias 
which could originate from these variables that 
could affect the frequency of malaria 
parasitaemia and occurrence of clinical malaria 
in pregnancy in the two groups during the study 
period. 
The low frequency of use of ITNs of 2.7% and 
3.0% for SP and proguanil groups respectively, 
is similar to the Nigerian National average of 
204.8%, , and has been attributed to the low level 
of awareness and poor distribution of the free 
insecticide treated bed nets provided by the 
20-24Federal Government of Nigeria .
The incidence of peripheral malaria 
parasitaemia at 34 weeks gestation of 6.3%, 
among the participants in the SP group, is lower 
15than 8.7% from southern Mozambique , 11.9% 
22 26from Benin city , and 10.4% from Ibadan , and 
may probably be because only primigravida 
were used in this study, which was not the case in 
these studies from southern Mozambique, Benin 
City and Ibadan, where multigravid pregnant 
women were also involved. This may be 
explained by the findings of Gies et al in Burkina 
27Faso , where it was found that SP is more 
effective in preventing malaria parasitaemia 
among primigravida than among women of 
higher parity. 
In this study, there was significant increase in the 
mean packed cell volume between recruitment 
and at 34 weeks gestation in each group, but there 
was no significant difference in the mean packed 
cell volume and number of participants who had 
malaria parasitaemia at 34 weeks gestation, and 
those who had severe anaemia and clinical 
malaria during the study period between the two 
groups, which agrees with the findings of other 
10,12,26studies. . This showed that the effectiveness 
of SP-IPTp in preventing malaria in pregnancy is 
 similar to that of proguanil,which shows that SP-
IPTp, is still effective in the prevention of 
malaria in pregnancy in Aminu Kano Teaching 
Hospital, despite reported cases of resistance in 
15-19southern Asia and some part of Africa . The 
similar mean packed cell volume between the 
two groups at recruitment showed that the base 
line PCV at recruitment did not contribute any 
bias in the final PCV at 34 weeks gestation. 
The low incidence of peripheral malaria 
parasitaemia at 34 weeks gestation in the two 
groups in this study, was also the finding of Ojo 
24et al , where it was said that women on SP-IPT 
with low peripheral malaria parasitaemia at 34 
weeks gestation, are most likely to have reduced 
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incidence of placental malaria parasitaemia and 
low birth weight babies, as well as favorable 
pregnancy outcome if followed to delivery. Also 
17 28 29Flemin et al , Aimaku et al , Steer , and Rana et 
30al  found that pregnant women with normal 
PCV are likely to have favorable pregnancy 
outcome. 
Haven confirmed in this study, that SP-IPTp is 
still effective in the prevention of malaria in 
pregnancy, with its sequel of anaemia, malaria 
parasitaemia and clinical malaria at Aminu 
Kano hospital, future studies on the efficacy of 
SP-IPTp in the prevention of placental malaria 
and low birth weight babies are recommended.
Limitations of the study: Patients in the 
Proguanil group used most of their tablets at 
home not as directly observed therapy, and the 
use of ITNs was also not directly observed.  
Conclusion: 
This study has showed that SP-IPTp is still 
effective in the prevention of malaria in 
pregnancy at Aminu Kano hospital. It has also 
showed that the use of two treatment doses of 
SP-IPTp, is associated with significant increase 
in the packed cell volume, significantly lower 
incidence of peripheral malarial parasitaemia 
and clinical malaria, and prevention of severe 
anaemia in pregnancy, which will go a long way 
in the realization of Millennium Development 
Goals 4 and 5.
Recommendations
The continued use of SP- IPTp is advocated for 
the prevention of malaria in pregnancy at Aminu 
Kano Teaching Hospital, in order to reduce 
maternal and fetal morbidity and mortality like 
maternal anaemia, congential malaria, low 
birthweight babies from intrauterine growth 
restriction (IUGR) and pretem delivery as well 
as the risk of Mother to Child Transmission of 
Human Immunodeficiency Virus.
Health facilities that use SP for IPTp, should 
carry out periodic surveillance on the efficacy of 
SP- IPTp, in order to detect early the occurrence 
of resistance to the drug, so that appropriate 
intervention can be instituted.
It is hoped that malaria vaccine that is being 
developed in the United States of America, 
which will address whatever lacuna there is in 
the national malaria control programs, will soon 
be made available in our hospital and 
communities in malaria endemic areas.
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Table3: Shows The Number Of Participants 
With Malaria Parasitaemia At 34 Weeks 
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